Anti-glycan antibodies and uses thereof
AssigneePTM Therapeutics, Inc.
InventorsLeonard Presta, Tony Liang, Jennifer Cheng
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.
Claims27
An antibody, or an antigen-binding portion thereof, that binds to sialyl Lewis A (sLeA) and sialyl Lewis C (sLeC), wherein the antibody or antigen-binding portion comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR-H1 comprising the sequence of SEQ ID NO:12, a CDR-H2 comprising the sequence of SEQ ID NO:13, and a CDR-H3 comprising the sequence of SEQ ID NO:14;
- and wherein the light chain variable region comprises a CDR-L1 comprising a sequence selected from the group consisting of SEQ ID NOs:15-17, a CDR-L2 comprising the sequence of SEQ ID NO:18, and a CDR-L3 comprising the sequence of SEQ ID NO:19.
Dependencies are inferred from the claim text.